AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26591117 — intervention group
Group type: EXPERIMENTAL
Intervention: Research group (celebration of Rare Disease Day)
Number of subjects: 242
Study 26591117 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 February 2013)
Number of subjects: 242
Study 26591117 — intervention group
Group type: EXPERIMENTAL
Intervention: Research group
Number of subjects: 242
Study 26591117 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 242
Study 22357109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab (0.25 mg/kg bodyweight bolus followed by 12 h intravenous infusion at 0.125 μg/kg per min)
Number of subjects: 2065
Study 22357109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 2065
Study 22357109 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 2065
Study 21115882 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally twice daily for 9 months
Number of subjects: 240
Study 21115882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 21115882 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 240
Study 18787429 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 55
Study 18787429 — intervention group
Group type: COMPARATOR
Intervention: Habitual lenses
Number of subjects: 55
Study 15893193 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 2 g/day
Number of subjects: 160
Study 15893193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 12948257 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) alone
Number of subjects: 13
Study 12948257 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) with Steinmann pin reinforcement
Number of subjects: 13
Study 12948257 — intervention group
Group type: COMPARATOR
Intervention: Normal distal femurs
Number of subjects: 13
Study 12948257 — intervention group
Group type: EXPERIMENTAL
Intervention: Defective femurs
Number of subjects: 13
Study 10390097 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day
Number of subjects: 12
Study 10390097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study 8661572 — intervention group
Group type: EXPERIMENTAL
Intervention: IV butylscopolamine (20 mg)
Number of subjects: 148
Study 8661572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dicyclomine (20 mg)
Number of subjects: 148
Study 8661572 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucagon (1 mg)
Number of subjects: 148
Study 8661572 — intervention group
Group type: COMPARATOR
Intervention: No-drug control group
Number of subjects: 148
Study 2004722 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 2004722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 2004722 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 2004722 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and Epinephrine mixture
Number of subjects: 0
Study 2004722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6858171 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothromblex500 (factor II, IX and X)
Number of subjects: 246
Study 6858171 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothromblex Total500 (factor II, VII, IX and X)
Number of subjects: 246
Study 6858171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both concentrates
Number of subjects: 246
Study 31711065 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 56
Study 31711065 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 56
Study 31711065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (rTMS and sham)
Number of subjects: 56
Study 31711065 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 56
Study 30745582 — intervention group
Group type: EXPERIMENTAL
Intervention: NK105 (65 mg/m2)
Number of subjects: 436
Study 30745582 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (PTX) (80 mg/m2)
Number of subjects: 436
Study 28407009 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive error treatment coverage in Indigenous Australians
Number of subjects: 4836
Study 28407009 — intervention group
Group type: COMPARATOR
Intervention: Refractive error treatment coverage in non-Indigenous Australians
Number of subjects: 4836
Study 28407009 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for low coverage in Indigenous Australians
Number of subjects: 4836
Study 28407009 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective factor for treatment of refractive error in Indigenous Australians
Number of subjects: 4836
Study 28407009 — intervention group
Group type: EXPERIMENTAL
Intervention: Coverage for Indigenous Australians who had not undergone an eye examination within the past five years
Number of subjects: 4836
Study 28407009 — intervention group
Group type: EXPERIMENTAL
Intervention: Coverage for Indigenous Australians who had never been examined
Number of subjects: 4836
Study 26503218 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-oriented training for health professionals (midwives and child health nurses)
Number of subjects: 206
Study 26503218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no process-oriented training)
Number of subjects: 206
Study 23499621 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogram-based AVO (SmartDelay)
Number of subjects: 280
Study 23499621 — intervention group
Group type: COMPARATOR
Intervention: Nominal atrioventricular delay (120 ms)
Number of subjects: 280
Study 21852546 — intervention group
Group type: EXPERIMENTAL
Intervention: H10407 at doses of 10(7) CFU with bicarbonate
Number of subjects: 35
Study 21852546 — intervention group
Group type: COMPARATOR
Intervention: Rechallenged volunteers (10 subjects)
Number of subjects: 35
Study 21852546 — intervention group
Group type: EXPERIMENTAL
Intervention: After the second challenge
Number of subjects: 35
Study 19651565 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (300 U/kg or 500 U/kg) administered every other day for 2 weeks
Number of subjects: 167
Study 19651565 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 167
Study 19651565 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (300 U/kg or 500 U/kg)
Number of subjects: 167
Study 17335320 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 605
Study 17335320 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 605
Study 17335320 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 605
Study 12413642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 50
Study 12413642 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol (beta-adrenergic antagonists)
Number of subjects: 50
Study 10705175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sennosides (Sen)
Number of subjects: 32
Study 10705175 — intervention group
Group type: COMPARATOR
Intervention: Non-sennosides (NSen)
Number of subjects: 32
Study 9366462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rocuronium (1,000 microg/kg for infants and 1,800 microg/kg for children)
Number of subjects: 29
Study 9366462 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rocuronium (not specified in detail)
Number of subjects: 29
Study 8456595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam (1600 mg/day)
Number of subjects: 96
Study 8456595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 3523298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg e.v./8 hours, starting the day before surgery to 10th day after it)
Number of subjects: 40
Study 3523298 — intervention group
Group type: COMPARATOR
Intervention: Void period (without specific therapy)
Number of subjects: 40
Study 29969209 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist pretreatment for three days
Number of subjects: 88
Study 29969209 — intervention group
Group type: COMPARATOR
Intervention: Conventional antagonist protocols
Number of subjects: 88
Study 26445354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic training
Number of subjects: 46
Study 26445354 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic training
Number of subjects: 46
Study 25495459 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD Group
Number of subjects: 1108
Study 25495459 — intervention group
Group type: COMPARATOR
Intervention: Standard Materials Group
Number of subjects: 1108
Study 22334531 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 28
Study 22334531 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 28
Study 20056900 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 317 75 mg
Number of subjects: 294
Study 20056900 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 317 150 mg
Number of subjects: 294
Study 20056900 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 317 300 mg
Number of subjects: 294
Study 20056900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 19343871 — intervention group
Group type: EXPERIMENTAL
Intervention: OXY‐TDS administration
Number of subjects: 0
Study 15721109 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (sirolimus and paclitaxel)
Number of subjects: 5066
Study 12743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20
Study 12743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + HRT
Number of subjects: 20
Study 12743626 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 10793931 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 386
Study 10793931 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 386
Study 8658029 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient evoked otoacoustic emissions (TEOAEs)
Number of subjects: 95
Study 8658029 — intervention group
Group type: COMPARATOR
Intervention: Pure-tone audiometry
Number of subjects: 95
Study 8658029 — intervention group
Group type: EXPERIMENTAL
Intervention: TEOAEs
Number of subjects: 95
Study 1888632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan (oral, administered for 14 days)
Number of subjects: 21
Study 6126752 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative external biliary drainage
Number of subjects: 57
Study 6126752 — intervention group
Group type: COMPARATOR
Intervention: No preoperative external biliary drainage
Number of subjects: 57
Study 30361793 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM‐LLLT with 5% potassium nitrate (KNO3)
Number of subjects: 50
Study 30361793 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM‐LLLT without potassium nitrate (KNO3)
Number of subjects: 50
Study 30361793 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate (KNO3) without PBM‐LLLT
Number of subjects: 50
Study 30361793 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel application with mock PBM‐LLLT
Number of subjects: 50
Study 30361793 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM‐LLLT and KNO3 combined
Number of subjects: 50
Study 30282144 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 3 ml (Group A)
Number of subjects: 80
Study 30282144 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml + physiological saline 1 ml (Group B)
Number of subjects: 80
Study 30282144 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 1 ml + physiological saline 2 ml (Group C)
Number of subjects: 80
Study 30282144 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline 3 ml (Group D)
Number of subjects: 80
Study 27553397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (education and support groups, involvement in quality assessment activities)
Number of subjects: 185
Study 27553397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 185
Study 25023641 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCABG)
Number of subjects: 106
Study 25023641 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (ONCABG)
Number of subjects: 106
Study 25023641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OPCABG and ONCABG)
Number of subjects: 106
Study 21817909 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL) alone
Number of subjects: 37
Study 21817909 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (DL) with TrachView videoscope
Number of subjects: 37
Study 21817909 — intervention group
Group type: EXPERIMENTAL
Intervention: TrachView videoscope
Number of subjects: 37
Study 20218984 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin (3000 U of anti-factor Xa once daily)
Number of subjects: 3239
Study 20218984 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (5000 IU t.i.d.)
Number of subjects: 3239
Study 20218984 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin
Number of subjects: 3239
Study 20218984 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3239
Study 17485070 — intervention group
Group type: EXPERIMENTAL
Intervention: GaA1As laser, lambda=660nm, power of 30mW, energy dose of 2J/cm(2), applied directly and perpendicularly into the cavity in a single visit.
Number of subjects: 8
Study 17485070 — intervention group
Group type: COMPARATOR
Intervention: No laser therapy (control group).
Number of subjects: 8
Study 15567809 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 200
Study 15567809 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 200
Study 11994808 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training at fast speed (2.0 mph)
Number of subjects: 24
Study 11994808 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training at slow speed (0.5 mph)
Number of subjects: 24
Study 11994808 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training at variable speeds (0.5, 1.0, 1.5, 2.0 mph)
Number of subjects: 24
Study 9816457 — intervention group
Group type: COMPARATOR
Intervention: Robot implantation
Number of subjects: 14
Study 9816457 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual implantation
Number of subjects: 14
Study 7695337 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg clavulanic acid with 2,000 mg amoxicillin
Number of subjects: 17
Study 7695337 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg clavulanic acid with 2,000 mg amoxicillin
Number of subjects: 17
Study 2239840 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% H3PO4 for 60 seconds
Number of subjects: 354
Study 2239840 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% H3PO4 for 15 seconds
Number of subjects: 354
Study 2239840 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% H3PO4 for 60 seconds
Number of subjects: 354
Study 7017081 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 (60 mg/sq m on Day 1) plus CCNU (130 mg/sq m on Day 2), repeated every 6 weeks
Number of subjects: 116
Study 7017081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 116
Study 7017081 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 plus CCNU
Number of subjects: 116
Study 7017081 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU alone
Number of subjects: 116
Study 7017081 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine
Number of subjects: 116
Study 7017081 — intervention group
Group type: EXPERIMENTAL
Intervention: Age under 50 years
Number of subjects: 116
Study 31904607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal wrist-spanning plate (DWSP) fixation to the second metacarpal (Group 1)
Number of subjects: 28
Study 31904607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal wrist-spanning plate (DWSP) fixation to the third metacarpal (Group 2)
Number of subjects: 28
Study 31904607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal wrist-spanning plate (DWSP) fixation to the third metacarpal with an intrafragmentary screw (Group 3)
Number of subjects: 28
Study 31505191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation
Number of subjects: 126
Study 31505191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lavender oil)
Number of subjects: 126
Study 29169500 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded endoluminal grafts
Number of subjects: 125
Study 29169500 — intervention group
Group type: COMPARATOR
Intervention: Femoropopliteal bypass
Number of subjects: 125
Study 26456233 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (2× RT)
Number of subjects: 54
Study 26456233 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly resistance training (1× RT)
Number of subjects: 54
Study 26456233 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly balance and tone (BAT)
Number of subjects: 54
Study 26456233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both resistance training groups (1× RT and 2× RT)
Number of subjects: 54
Study 25608543 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based peer leader centered smoking prevention program (5 sessions)
Number of subjects: 174
Study 25608543 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 minute lecture)
Number of subjects: 174
Study 21091860 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 247
Study 19438432 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (n = 30) applied once daily for 6 months
Number of subjects: 60
Study 19438432 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n = 30) applied once daily for 6 months
Number of subjects: 60
Study 19438432 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (n = 15)
Number of subjects: 60
Study 19438432 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n = 13)
Number of subjects: 60
Study 19438432 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (n = 15) for 6 months
Number of subjects: 60
Study 17554147 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment (20, 35, or 50 microg/kg per day)
Number of subjects: 139
Study 17554147 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 139
Study 17554147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 16818924 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TCA)
Number of subjects: 1007
Study 16818924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 1007
Study 16818924 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 1007
Study 16818924 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between TCA and sham acupuncture
Number of subjects: 1007
Study 12657990 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of PGE(1) (20 microg) solution
Number of subjects: 57
Study 12657990 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of saline solution
Number of subjects: 57
Study 12657990 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of dexamethasone (8 mg) solution
Number of subjects: 57
Study 10224546 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane condom
Number of subjects: 805
Study 10224546 — intervention group
Group type: COMPARATOR
Intervention: Latex condom
Number of subjects: 805
Study 8807140 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic techniques for identifying functional mutations in complex human disorders
Number of subjects: 6000
Study 8807140 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to different anti-hypertensive agents
Number of subjects: 6000
Study 8807140 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence risk for hypertension
Number of subjects: 6000
Study 8807140 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial history of hypertension
Number of subjects: 6000
Study 8807140 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors in hypertension
Number of subjects: 6000
Study 1860198 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day)
Number of subjects: 1330
Study 1860198 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (dose-adjusted to prolong prothrombin time to 1.3-1.8 times control)
Number of subjects: 1330
Study 1860198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1330
Study 1860198 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1330
Study 1860198 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1330
Study 6192381 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 167
Study 6192381 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon arc photocoagulation
Number of subjects: 167
Study 6192381 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 167
Study 29402572 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling by a trained oncology nurse
Number of subjects: 240
Study 29402572 — intervention group
Group type: COMPARATOR
Intervention: Standard generic information by a physician
Number of subjects: 240
Study 26952969 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle guide
Number of subjects: 25
Study 26952969 — intervention group
Group type: COMPARATOR
Intervention: Normal trials (without needle guide)
Number of subjects: 25
Study 25904220 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 50 mg
Number of subjects: 0
Study 25904220 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 100 mg
Number of subjects: 0
Study 25904220 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 200 mg
Number of subjects: 0